GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » FCF Margin %

NexImmune (NexImmune) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NexImmune FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NexImmune's Free Cash Flow for the three months ended in Dec. 2023 was $-5.83 Mil. NexImmune's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, NexImmune's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, NexImmune's current FCF Yield % is -721.83%.

The historical rank and industry rank for NexImmune's FCF Margin % or its related term are showing as below:


NEXI's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -149.8
* Ranked among companies with meaningful FCF Margin % only.

NexImmune FCF Margin % Historical Data

The historical data trend for NexImmune's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune FCF Margin % Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial - - - - -

NexImmune Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NexImmune's FCF Margin %

For the Biotechnology subindustry, NexImmune's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexImmune's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NexImmune's FCF Margin % falls into.


NexImmune FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NexImmune's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-31.479/0
= %

NexImmune's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-5.833/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune FCF Margin % Related Terms

Thank you for viewing the detailed overview of NexImmune's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune (NexImmune) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » FCF Margin %
Comparable Companies
FWBI REVB ZVSA IPIX QLGN ENVB GRTX PSTV AXIM ARDS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
Website
https://www.neximmune.com
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
Alan S. Roemer director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover officer: VP, Corporate Controller C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao director 10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi director C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke officer: Chief Science Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones officer: Chief Operating Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis officer: EVP of R&D 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer director, officer: President and CEO C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer officer: Chief Financial Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight officer: Chief Medical Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877